Cefadroxil is a first-generation cephalosporin antibiotic that has been widely used for the treatment of various bacterial infections. It is a semisynthetic derivative of cephalosporin C and belongs to the beta-lactam class of antibiotics. Its chemical structure features a dihydrothiazine ring fused to a beta-lactam ring, with a side chain that confers its specific antibacterial activity. Cefadroxil is available in oral formulations, typically as capsules, tablets, or oral suspension, and is known for its good absorption and extended half-life compared to some other first-generation cephalosporins.

The primary mechanism of action of cefadroxil is the inhibition of bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, which are enzymes responsible for the final cross-linking steps of peptidoglycan assembly. By interfering with this process, cefadroxil disrupts the integrity of the cell wall, leading to osmotic lysis and bacterial death. This mechanism is bactericidal and is most effective against actively dividing bacteria. Cefadroxil exhibits activity primarily against Gram-positive bacteria, including Streptococcus pyogenes, Streptococcus pneumoniae, and Staphylococcus aureus (including non-penicillinase-producing strains). It also has moderate activity against some Gram-negative organisms such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, but is generally less effective against Gram-negative bacteria compared to later-generation cephalosporins.

Pharmacokinetically, cefadroxil is well absorbed after oral administration with a bioavailability of approximately 90%. Food does not significantly affect its absorption, although taking it with meals may slow the rate. Peak serum concentrations are achieved within 1 to 2 hours. The drug is widely distributed throughout body tissues and fluids, including the tonsils, sinuses, bone, bile, and pleural fluid, but penetration into the cerebrospinal fluid is poor, making it unsuitable for the treatment of meningitis. Cefadroxil is primarily excreted unchanged by the kidneys via glomerular filtration and tubular secretion, with a plasma elimination half-life of about 1.5 to 2 hours in individuals with normal renal function. This half-life is longer than that of cephalexin, allowing for less frequent dosing (typically twice daily). Renal impairment prolongs the half-life, requiring dose adjustment in patients with significant kidney dysfunction.

The clinical indications for cefadroxil include a variety of mild to moderate infections caused by susceptible organisms. It is commonly prescribed for upper respiratory tract infections such as pharyngitis, tonsillitis, and sinusitis, especially those due to Streptococcus pyogenes. It is also effective for skin and soft tissue infections, including impetigo, cellulitis, and wound infections. Additionally, cefadroxil is used in the treatment of urinary tract infections (UTIs) caused by susceptible strains of E. coli, K. pneumoniae, and P. mirabilis. Less common uses include bone and joint infections, though these often require higher doses or combination therapy. It is important to note that cefadroxil is not active against methicillin-resistant Staphylococcus aureus (MRSA) or most anaerobic bacteria, and it has limited activity against Pseudomonas species.

The standard dosing for adults is 1 to 2 grams per day, divided into two doses, depending on the severity of the infection. For pediatric patients, the dosage is typically 30 mg/kg per day in divided doses. For https://Veranomartins.es, streptococcal pharyngitis, a once-daily dose of 1 gram is sometimes used due to the drug’s extended half-life. Treatment duration is usually 7 to 14 days, depending on the infection type. Dose adjustments are necessary for patients with creatinine clearance below 50 mL/min; for those with severe renal impairment, the interval may need to be extended.

Cefadroxil is generally well tolerated, with a safety profile similar to other first-generation cephalosporins. Common side effects include gastrointestinal disturbances such as diarrhea, nausea, vomiting, and dyspepsia. Hypersensitivity reactions are possible, ranging from mild skin rashes to rare cases of anaphylaxis. Patients with a history of penicillin allergy have a cross-sensitivity risk of about 5–10%, so caution is advised. Other adverse effects include headache, dizziness, and transient increases in liver enzymes. Pseudomembranous colitis caused by Clostridium difficile has been reported, as with many antibiotics. Prolonged use may lead to overgrowth of non-susceptible organisms, including Candida and resistant bacteria.

Contraindications include known hypersensitivity to cefadroxil or any cephalosporin. It should be used with caution in patients with a history of gastrointestinal disease, particularly colitis, and in those with renal impairment. Pregnancy category B indicates that animal studies have not shown risk, but adequate human studies are lacking; it should be used only if clearly needed. Cefadroxil is excreted in breast milk in small amounts, so nursing mothers should weigh benefits against risks.

Drug interactions include potential nephrotoxicity when combined with aminoglycosides, loop diuretics, or other nephrotoxic agents. Probenecid can reduce renal excretion of cefadroxil, increasing its serum concentration. Anticoagulants such as warfarin may have enhanced effects due to alteration of gut flora and vitamin K production, though this interaction is less prominent than with some other antibiotics. False-positive urine glucose tests using copper reduction methods (e.g., Benedict’s solution) may occur, but not with glucose oxidase methods. Direct Coombs test positivity can also be seen.

In terms of resistance, bacterial resistance to cefadroxil can develop through several mechanisms, including production of beta-lactamases that hydrolyze the beta-lactam ring, alteration of PBPs with reduced affinity, and decreased permeability or efflux pumps. Among Gram-positive bacteria, resistance is particularly seen in MRSA and penicillin-resistant pneumococci. Extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria are also resistant. Therefore, local resistance patterns should guide empiric therapy.

Comparatively, cefadroxil is similar to cephalexin but has a longer half-life, allowing less frequent dosing. It is more acid-stable than some other first-generation agents. However, for certain infections, such as uncomplicated UTIs, first-generation cephalosporins are still effective options. For more severe or hospital-acquired infections, broader-spectrum cephalosporins (e.g., cefuroxime, ceftriaxone) are preferred.

Overall, cefadroxil remains a useful antibiotic in outpatient settings for treating common infections caused by susceptible bacteria. Its once- or twice-daily dosing improves patient compliance. Careful consideration of the infection site, suspected pathogens, patient history, and renal function is necessary to optimize therapy and minimize adverse effects. As with all antibiotics, judicious use is recommended to preserve its efficacy and combat antimicrobial resistance.